INTRODUCTION
N N Multiple myeloma (MM) is a cancer of plasma cells of the bone marrow, and the 5-year survival rate among patients with MM is 45%. 1, 2 N N Treatment practices are changing rapidly, with novel agents and stem cell transplantation now recommended for MM treatment. 3 N N An analysis of data from 1999-2007 found that use of traditional chemotherapies has decreased substantially in the US, while use of novel agents (thalidomide, bortezomib, and lenalidomide) has increased. 4 N N Despite the availability of novel therapies and a general improvement in survival, the unmet need continues to be high, with patients requiring multiple lines of treatment.
N N As patients go through multiple relapses, the complexity of treatment regimens increases, likely increasing the burden on healthcare resources.
N N The current analysis evaluates treatment regimens, sequences, and associated healthcare costs across lines of therapy of patients who have initiated a 2nd-line (2L) therapy.
Objectives
N N To evaluate treatment sequences and associated healthcare costs among patients with relapsed or refractory multiple myeloma (RRMM) who have initiated a 2L therapy. ---Most frequent treatment regimens used in 2L (1 prior therapy) and in 3L/4L (>2 prior therapies) were calculated overall and by prior immunomodulatory drug (IMiD) exposure (i.e. in any of the prior lines).
Methods

Study design
---Common treatment sequences of treatment regimens were evaluated. N N Costs were calculated monthly. Average cost measures were reported for treatment regimens and presented by line of therapy. Mean monthly healthcare costs for each cohort were adjusted for censoring.
---The mean monthly cost of the cohort was estimated by considering both the estimated costs for censored patients and the actual costs for non-censored patients.
Results
Patients N N A total of 4449 patients were identified as initiating 2L treatment for MM.
Of these:
---1696 (38%) progressed to 3L ---689 (15%) progressed to 4L. N N Median follow-up time was 14 months (range . N N Baseline characteristics of patients with RRMM by line of therapy are described in Table 1 .
N N Median time from start of 2L to start of 3L treatment was 5.8 months.
Median time from start of 3L to start of 4L treatment was x.x months.
N N The most frequent 2L regimens were lenalidomide, lenalidomidedexamethasone, bortezomib-dexamethasone, bortezomib-lenalidomidedexamethasone, and bortezomib (Figure 1) . The most commonly observed regimens used across 2L-4L are also presented in Figure 1 . N N Of patients whose prior therapy included an IMiD, bortezomibdexamethasone was the most common 2L regimen. N N For patients with no prior IMiD exposure, lenalidomide was the most common 2L treatment. N N Treatment sequences included switches between IMiDs and proteasome inhibitors (PIs).
---Among the 27% of patients taking lenalidomide in 2L who then progressed to 3L, 64% had bortezomib-based regimens in 3L.
---Among the 47% of patients taking bortezomib-dexamethasone in 2L who then progressed to 3L, 63% had lenalidomide-based regimens in 3L.
N N MM-specific costs were highest for all patients during the first year of 2L treatment compared with subsequent months thereafter (Figure 2 ).
---This trend was consistent regardless of 2L treatment regimen initiated.
N N All drug-related costs accounted for 39-62% of all-cause costs and were dependent on regimen and treatment line (Figure 3 ).
---For the overall cohort, MM-specific drug-related costs, including regimen and supportive therapies, accounted for 41.5% over a 3-year period.
N N Cumulative monthly post-progression costs over 36 months were higher for all treatments ( Table 2 ).
---MM-specific costs after progression from 2L were higher by $122,823 compared with costs incurred pre-progression to a 2L treatment ( N N Progression to subsequent treatment lines was dependent on an algorithm based on the timing of administrative claims. As these data are collected for billing and reimbursement, rather than for clinical factors, misclassification of treatment regimens identified within the lines of therapy is possible.
